Cargando…

1400. Pretomanid in the Treatment of Patients with Tuberculosis in the United States: the Bedaquiline, Pretomanid and Linezolid (BPaL) Accelerated Monitoring (BAM) Project

BACKGROUND: In August 2019 the U.S. FDA approved pretomanid as part of a 6-month all-oral BPaL (bedaquiline, pretomanid, and linezolid) regimen for treating pulmonary extensively drug-resistant (XDR) or treatment-intolerant or nonresponsive multidrug-resistant (MDR) tuberculosis (TB). In the study s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Goswami, Neela, Peddareddy, Lakshmi Praveena, Jereb, John, Semidey, Angel Colon, Darnall, Elaine, Macias, Patricia, Jasuja, Supriya, Landers, Karen, Dasgupta, Shom, Oxtoby, Margaret, Spitters, Christopher, Dov, Lana, Narita, Masa, DaSilva, Malini, Cropper, Tracina, Gullickson, Cricket, Ashkin, David, Haley, Connie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8643925/ http://dx.doi.org/10.1093/ofid/ofab466.1592

Ejemplares similares

Baseline and acquired resistance to bedaquiline, linezolid and pretomanid, and impact on treatment outcomes in four tuberculosis clinical trials containing pretomanid
por: Timm, Juliano, et al.
Publicado: (2023)

Pretomanid with bedaquiline and linezolid for drug-resistant TB: a comparison of prospective cohorts
por: Oelofse, S., et al.
Publicado: (2021)

Genetic diversity of candidate loci linked to Mycobacterium tuberculosis resistance to bedaquiline, delamanid and pretomanid
por: Gómez-González, Paula J., et al.
Publicado: (2021)

Population Pharmacokinetics of the Antituberculosis Agent Pretomanid
por: Salinger, David H., et al.
Publicado: (2019)

Delamanid or pretomanid? A Solomonic judgement!
por: Mudde, Saskia E., et al.
Publicado: (2022)

Contribution of Pretomanid to Novel Regimens Containing Bedaquiline with either Linezolid or Moxifloxacin and Pyrazinamide in Murine Models of Tuberculosis
por: Xu, Jian, et al.
Publicado: (2019)

Bactericidal and Sterilizing Activity of a Novel Regimen with Bedaquiline, Pretomanid, Moxifloxacin, and Pyrazinamide in a Murine Model of Tuberculosis
por: Li, Si-Yang, et al.
Publicado: (2017)

Bedaquiline, pretomanid and linezolid for treatment of extensively drug resistant, intolerant or non-responsive multidrug resistant pulmonary tuberculosis
por: Conradie, Francesca, et al.
Publicado: (2020)

Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the Philippines
por: Gomez, Gabriela Beatriz, et al.
Publicado: (2021)

An Exposure-Response Perspective on the Clinical Dose of Pretomanid
por: Nedelman, Jerry R., et al.
Publicado: (2020)

Male reproductive hormones in patients treated with pretomanid
por: Boekelheide, K., et al.
Publicado: (2022)

Pretomanid for tuberculosis treatment: an update for clinical purposes
por: Occhineri, Sara, et al.
Publicado: (2022)

Predictions of Bedaquiline and Pretomanid Target Attainment in Lung Lesions of Tuberculosis Patients using Translational Minimal Physiologically Based Pharmacokinetic Modeling
por: Mehta, Krina, et al.
Publicado: (2023)

Promise and Peril of Pretomanid–Rifamycin Regimens for Drug-susceptible Tuberculosis
por: Velásquez, Gustavo E., et al.
Publicado: (2023)

A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB
por: Tweed, C. D., et al.
Publicado: (2021)

Profiling Pretomanid as a Therapeutic Option for TB Infection: Evidence to Date
por: Stancil, Stephani L, et al.
Publicado: (2021)

Ancient and recent differences in the intrinsic susceptibility of Mycobacterium tuberculosis complex to pretomanid
por: Bateson, Anna, et al.
Publicado: (2022)

Toxicity and toxicokinetic assessment of an anti-tubercular drug pretomanid in cynomolgus monkeys
por: Bruning-Barry, Rebecca, et al.
Publicado: (2022)

Short and Efficient Synthesis of the Antituberculosis Agent Pretomanid from (R)-Glycidol
por: Lucas, Tobias, et al.
Publicado: (2023)

Untargeted metabolomics reveals a new mode of action of pretomanid (PA-824)
por: Baptista, Rafael, et al.
Publicado: (2018)

Antitubercular Nitroimidazoles Revisited: Synthesis and Activity of the Authentic 3-Nitro Isomer of Pretomanid
por: Thompson, Andrew M., et al.
Publicado: (2017)

Long-Term Effects on QT Prolongation of Pretomanid Alone and in Combinations in Patients with Tuberculosis
por: Li, Hanbin, et al.
Publicado: (2019)

Assessment of the Carcinogenic Potential of Pretomanid in Transgenic Tg.rasH2 Mice
por: Ambroso, Jeffrey L., et al.
Publicado: (2022)

Characterizing Absorption Properties of Dispersible Pretomanid Tablets Using Population Pharmacokinetic Modelling
por: Zou, Yuanxi, et al.
Publicado: (2022)

Fed- and Fasted-State Performance of Pretomanid Amorphous Solid Dispersions Formulated with an Enteric Polymer
por: Nguyen, Hanh Thuy, et al.
Publicado: (2023)

Duration of pretomanid/moxifloxacin/pyrazinamide therapy compared with standard therapy based on time-to-extinction mathematics
por: Srivastava, Shashikant, et al.
Publicado: (2020)

Pretomanid dose selection for pulmonary tuberculosis: An application of multi‐objective optimization to dosage regimen design
por: Lyons, Michael A.
Publicado: (2021)

Dynamic (18)F-Pretomanid PET imaging in animal models of TB meningitis and human studies
por: Mota, Filipa, et al.
Publicado: (2022)

DprE2 is a molecular target of the anti-tubercular nitroimidazole compounds pretomanid and delamanid
por: Abrahams, Katherine A., et al.
Publicado: (2023)

Randomised trial to evaluate the effectiveness and safety of varying doses of linezolid with bedaquiline and pretomanid in adults with pre-extensively drug-resistant or treatment intolerant/non-responsive multidrug-resistant pulmonary tuberculosis: study protocol
por: Padmapriyadarsini, Chandrasekaran, et al.
Publicado: (2022)

Genetic and Virulence Characteristics of Linezolid and Pretomanid Dual Drug-Resistant Strains Induced from Mycobacterium tuberculosis in vitro
por: Hu, Minghao, et al.
Publicado: (2020)

Phase 1 Study of the Effects of the Tuberculosis Treatment Pretomanid, Alone and in Combination With Moxifloxacin, on the QTc Interval in Healthy Volunteers
por: Li, Mengchun, et al.
Publicado: (2020)

Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial
por: Tweed, Conor D, et al.
Publicado: (2019)

TB-PRACTECAL: study protocol for a randomised, controlled, open-label, phase II–III trial to evaluate the safety and efficacy of regimens containing bedaquiline and pretomanid for the treatment of adult patients with pulmonary multidrug-resistant tuberculosis
por: Berry, Catherine, et al.
Publicado: (2022)

Next-Generation Diarylquinolines Improve Sterilizing Activity of Regimens with Pretomanid and the Novel Oxazolidinone TBI-223 in a Mouse Tuberculosis Model
por: Li, Si-Yang, et al.
Publicado: (2023)

Efficacy of PBTZ169 and pretomanid against Mycobacterium avium, Mycobacterium abscessus, Mycobacterium chelonae, and Mycobacterium fortuitum in BALB/c mice models
por: Zheng, Luyao, et al.
Publicado: (2023)

2354. Implementation of BPaL in the United States: Experience using a novel all-oral treatment regimen for rifampin-resistant or treatment-intolerant TB disease
por: Haley, Connie A, et al.
Publicado: (2022)

1411. Noninvasive Assessment of Intralesional Antimicrobial Concentration-Time Profiles in Pulmonary and Central Nervous System Tuberculosis using Dynamic (18)F-Pretomanid Positron Emission Tomography
por: Mota, Filipa, et al.
Publicado: (2021)

Budgetary impact of using BPaL for treating extensively drug-resistant tuberculosis
por: Mulder, Christiaan, et al.
Publicado: (2022)

Assessment of a pretomanid analogue library for African trypanosomiasis: Hit-to-lead studies on 6-substituted 2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]thiazine 8-oxides
por: Thompson, Andrew M., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_cfltr0huso22ld3i4b6fv2pdrg